The Effect of Primaquine on Gametocyte Development and Clearance in the Treatment of Uncomplicated Falciparum Malaria With Dihydroartemisinin-Piperaquine in South Sumatra, Western Indonesia: An Open-Label, Randomized, Controlled Trial by Syafruddin D
M A J O R A R T I C L E
The Effect of Primaquine on Gametocyte
Development and Clearance in the Treatment
of Uncomplicated Falciparum Malaria With
Dihydroartemisinin-Piperaquine in South
Sumatra, Western Indonesia: An Open-Label,
Randomized, Controlled Trial
Inge Sutanto,1 Sri Suprijanto,2 Ayleen Kosasih,1 Muhamad S. Dahlan,3 Din Syafruddin,4 Rita Kusriastuti,2 William
A. Hawley,5 Neil F. Lobo,6 and Feiko O. ter Kuile7
1Department of Parasitology, Faculty of Medicine, University of Indonesia, 2Malaria Subdirectorate, Communicable Disease Control, Ministry of Health,
Republic of Indonesia, 3Epidemiologi Indonesia Company, 4Eijkman Institute for Molecular Biology, and 5United Nations Children’s Fund, Jakarta, Indonesia;
6Eck Institute for Global Health and Infectious Diseases, University of Notre Dame, Indiana; and 7Liverpool School of Tropical Medicine, United Kingdom
(See the Editorial Commentary by Dondorp on pages 694–6 and the Electronic Article by Das et al on pages e48–e58.)
Background. Artemisinin-based combination therapy is very effective in clearing asexual stages of malaria
and reduces gametocytemia, but may not affect mature gametocytes. Primaquine is the only commercially avail-
able drug that eliminates mature gametocytes.
Methods. We conducted a 2-arm, open-label, randomized, controlled trial to evaluate the efﬁcacy of single-dose
primaquine (0.75 mg/kg) following treatment with dihydroartemisinin-piperaquine (DHP) on Plasmodium falciparum
gametocytemia, in Indonesia. Patients aged ≥5 years with uncomplicated falciparum malaria, normal glucose-6-
phosphate dehydrogenase enzyme levels, and hemoglobin levels ≥8 g/dL were assigned by computerized-generating se-
quence to a standard 3-day course of DHP alone (n = 178) or DHP combined with a single dose of primaquine on day 3
(n = 171). Patients were seen on days 1, 2, 3, and 7 and then weekly for 42 days to assess the presence of gametocytes and
asexual parasites by microscopy. Survival analysis was stratiﬁed by the presence of gametocytes on day 3.
Results. DHP prevented development of gametocytes in 277 patients without gametocytes on day 3. In the game-
tocytemic patients (n = 72), primaquine was associated with faster gametocyte clearance (hazard ratio = 2.42 [95%
conﬁdence interval, 1.39–4.19], P = .002) and reduced gametocyte densities (P = .018). The day 42 cure rate of asexual
stages in the DHP + primaquine and DHP-only arms were: polymerase chain reaction (PCR) unadjusted, 98.7% vs
99.4%, respectively; PCR adjusted, 100% for both. Primaquine was well tolerated.
Conclusions. Addition of single-dose 0.75 mg/kg primaquine shortens the infectivity period of DHP-treated
patients and should be considered in low-transmission regions that aim to control and ultimately eliminate falciparum
malaria.
Clinical Trials Registration. NCT01392014.
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The World Health Organization recommends that a
single dose of primaquine (PQ) be added to standard
blood schizonticidal therapy of Plasmodium falcipa-
rum malaria because of its gametocidal effect and
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potential transmission-blocking activity [1]. Primaquine is a
member of the 8-aminoquinolines approved by the US Food
and Drug Administration in 1952 and one of the older anti-
malarials still in widespread use. Its use has received renewed
attention with the increased interest in malaria elimination [2].
However, the use of PQ to reduce malaria transmission is con-
troversial. Although it only adds $0.05 to the cost of therapy [3],
PQ can cause severe and occasionally life-threatening hemoly-
sis in patients with severe glucose-6-phosphate dehydrogenase
(G6PD) deﬁciency. Moreover, the artemisinins themselves,
which are part of artemisinin-based combination therapy
(ACT), are very efﬁcient in inhibiting the growth of asexual
stages, thereby indirectly inhibiting the development of
P. falciparum gametocytes by reducing the asexual stage pro-
genitors [4, 5]. Furthermore, numerous in vitro studies suggest
that artemisinin derivatives may directly inhibit the develop-
ment of young P. falciparum gametocytes into mature gameto-
cytes [6, 7]. Mature gametocytes can be present in the
peripheral circulation for several weeks to allow ingestion by
the mosquito vector [8]. Hence, antimalarial drug treatments
that can reduce the development of these late-stage gameto-
cytes may play a key role in the elimination of malaria trans-
mission. However, some studies suggest that artemisinins
alone or in combination with other drugs merely reduce the
number of immature gametocytes and are not effective in
eradicating all mature gametocytes; consequently, patients un-
dergoing ACT may remain infectious for 2–4 weeks [9–14].
Thus, additional drugs such as PQ that act directly against
mature gametocytes may be needed to eliminate transmission
in communities [1, 15].
In Indonesia, dihydroartemisinin-piperaquine (DHP) has
been the ﬁrst-line treatment for both uncomplicated P. falcipa-
rum and Plasmodium vivax infections since 2010. The risk of
P. falciparum gametocytemia is higher after treatment with
DHP than with other ACTs, possibly reﬂecting the relatively
lower dose of artemisinins in DHP [16]. The national policy
also includes the use of a single dose of PQ 0.75 mg/kg in ad-
dition to DHP; however, with the exception of the bigger
health centers and hospitals, screening for G6PD deﬁciency is
usually unavailable, limiting the implementation of the recom-
mendation. Further, the effectiveness of primaquine in reduc-
ing gametocytes has never been evaluated in DHP-treated
patients in Indonesia. The present trial was designed to deter-
mine the risk-beneﬁt proﬁle of a single dose of PQ when
given directly following treatment with DHP.
MATERIALS AND METHODS
Study Site
The study was conducted between December 2008 and March
2010 at Hanura Primary Health Center, Padang Cermin district,
Lampung province (105°45′–103°48′E and 3°45′–6°45′S)
located at the southern end of Sumatra. The health center was
the only place in the immediate area providing artemisinin-
based combination drugs for antimalarial treatment. Nearby
abandoned shrimp cultivation ponds provide larval habitat for
Anopheles sundaicus, an efﬁcient and important malaria vector
in the region [17]. Seasonal malaria transmission peaks follow-
ing the rainy season between September and April. At the time
of the study, artesunate-amodiaquine with a single dose of PQ
was the ﬁrst-line therapy for patients with P. falciparum infec-
tion. High-grade chloroquine resistance to both P. falciparum
and P. vivax is well established in the area [18]. Community-
based surveys showed that the study area had low malaria ende-
micity with a malaria prevalence of 1.8% across all age groups
at the time of this study (Sutanto et al, unpublished data).
Participants
This was a single-center, open-label, 2-arm, randomized, con-
trolled superiority trial in patients with fever or a history of
fever within the past 24 hours with microscopically conﬁrmed
P. falciparum infection, regardless of the presence of gameto-
cyte stages. Inclusion criteria consisted of (1) parasite density
≥1000 parasites/µL; (2) age ≥5 years; (3) normal glucose-6-
phosphate dehydrogenase (G6PD) enzyme levels based on a
qualitative test; (4) hemoglobin level ≥8 g/dL; (5) negative
pregnancy test (assessed by human chorionic gonadotropin
urine test) or not breastfeeding; (6) no signs of severe malnu-
trition; (7) no other chronic diseases; (8) no history of allergy
to the study drugs; (9) ability to return for 42 days of follow-
up. A history of previous antimalarial drug use was not an
exclusion criterion. The protocol was approved by the Ethical
Committee of the Faculty of Medicine, University of Indone-
sia, Jakarta.
Procedures
Subjects received a standard 3-day course of DHP (ﬁxed-dose
tablets of 40 mg dihydroartemisinin and 320 mg piperaquine;
D-ARTEPP, Guilin Pharmaceutical Co, Ltd) with primaquine
(DHP + PQ arm) or without it (DHP-only arm). The daily
DHP regimen was based on weight (≥41 kg: 3 tablets; 31–40
kg: 2 tablets; 18–30 kg: 1 tablet). The total dose of dihydroar-
temisinin ranged 4–10.9 mg/kg, and piperaquine ranged 32–
87.3 mg/kg. In the DHP + PQ arm, a single dose of PQ
(15 mg base, PT Phapros Tb) was given on day 3 to achieve a
dose of 0.75 mg/kg, rounded to the nearest half tablet. The
mean dose was 0.74 mg/kg (range, 0.5–0.94 mg/kg). Modeling
has suggested that the greatest impact of primaquine on game-
tocytes can be achieved by administrating primaquine on day
8 after the start of symptoms [19]. Self-treatment and corre-
sponding delay in seeking care from health centers are
common in Indonesia, such that many patients attend clinic
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several days after the onset of symptoms. We therefore chose
to administer PQ on day 3 to maximize the delay of PQ ad-
ministration while minimizing the impact on compliance.
All treatment doses were given as directly observed therapy
by the healthcare attendants. If the patient vomited within 30
minutes, the same dose was repeated. If drug vomiting reoc-
curred, the subject was excluded. Before taking the tablets,
each subject ate biscuits provided by the study. Both manufac-
turers provided certiﬁcates of analysis for the batches used in
the study, and fulﬁlled standards for good manufacturing
practices in China and Indonesia, respectively.
Subjects with fever (≥38.5°C using tympanic membrane
measurement) received acetaminophen (paracetamol). Sub-
jects were requested to return to the health center on days 1,
2, 3, 7, 14, 21, 28, 35, and 42, and any other day in between if
they felt ill. At each scheduled visit (except on day 1) a ﬁnger-
prick blood sample was collected for malaria blood smears
and dried blood blots for parasite genotyping (100 µL of
blood on Whatman FTA ﬁlter paper). Patients found to be
parasitemic on day 7 or later were treated with quinine
(3 × 10 mg/kg/day for 7 days). Compliance or outcome follow-
ing treatment with quinine was not monitored.
Thick and thin blood smears were stained with 3% Giemsa
solution for 40 minutes. The number of asexual parasites was
counted against 200 leukocytes and expressed per microliter
assuming a leukocyte count of 8000 cells/µL blood. If <10 par-
asites were detected in the ﬁrst 200 leukocytes, counting was
continued against 500 leukocytes. If no parasites were detect-
ed, 100 ﬁelds were examined before a smear was declared neg-
ative. The counting of sexual-stage parasites was always
against 500 leukocytes. Blood smears were read independently
by 2 laboratory technicians, in the ﬁeld (unblinded to the
treatment allocation) and in the central laboratory in Jakarta
(blinded). In case of disagreement, a third reader (blinded)
reread the slide and ﬁnal results were based on the third
reader’s evaluation. Parasite densities were determined using
the average parasite counts from both technicians. Hemoglo-
bin levels were assessed on days 0, 7, and 42 using a
HemoCue system (Hb 201+, Angelholm, Sweden). G6PD deﬁ-
ciency was deﬁned using qualitative assays based on the ﬂuo-
rescent spot test (Trinity Biotech, cat no. 203-A).
Molecular analysis to distinguish reinfections from recru-
descences of P. falciparum was performed at the Eijkman In-
stitute, Jakarta, by genotyping GLURP, MSP2, and MSP1 in
paired samples of treatment failures [20, 21].
Randomization and Masking
A computerized randomization sequence was prepared in
advance. Block sizes of 4 were used to ensure equal distribu-
tion across the study arms by time. Allocation concealment
was achieved by using prenumbered opaque and sealed
envelopes. Eligible subjects were randomized sequentially by
drawing successive envelopes according to their order on the
patient list at the healthcare center.
Outcomes and Sample Size
The main objective was to determine the effect of the standard
single dose of primaquine in addition to the completed 3-day
treatment with DHP on gametocyte carriage. This was done
by comparing the overall risk of gametocyte carriages on day
7 and then weekly till day 42, to measure the combined effect
on gametocyte development and clearance (primary end-
point). This 2-arm trial required 165 patients per arm to
detect a 7% absolute reduction in the prevalence of gameto-
cytes following the week after treatment with primaquine
from 9% in the DHP-only arm to 2% in the DHP + PQ arm
with 80% power and a 2-sided α of .05. The anticipated game-
tocyte prevalence of 9% was based on the day 7 prevalence
in an earlier study with DHP (Sutanto et al, unpublished
data). We planned to recruit 200 patients per arm, to allow
for 17.5% loss to follow-up, but recruitment was stopped
earlier because the success rate of follow-up was higher than
anticipated.
We also assessed the impact on gametocytes using the fol-
lowing secondary endpoints: (1) the gametocyte clearance
rates by day 42 in patients with gametocytes on day 3, (2) the
incidence of gametocyte development by day 42 in patients
who were gametocyte free on day 3, and (3) gametocyte densi-
ties between days 3 and 42 inclusive. Other endpoints includ-
ed the effect of primaquine on recurrence of the asexual stages
of P. falciparum, polymerase chain reaction (PCR) adjusted
and unadjusted for reinfections.
Adverse events were evaluated using a questionnaire
prompting for symptoms of headache, weakness, nausea, vom-
iting, abdominal pain, diarrhea, itching, and paresthesia.
Statistical Analysis
Modiﬁed intent-to-treat analysis of the effect of PQ was used,
and the evaluable population included all patients that were
seen on day 3. Patients who withdrew, were lost to follow-up,
or had protocol deviations before day 3 inclusive were exclud-
ed from the analysis; however they were included if these
events occurred after day 3.
Data were analyzed using Stata software, version 10.0. Dif-
ferences in gametocyte prevalence were compared using the
prevalence ratio (PR) and corresponding 95% conﬁdence in-
terval (CI), along with P values using χ2 test or Fisher exact
test. The therapeutic response to treatment was assessed by
calculating the cumulative risks of recurrence of asexual para-
sites (unadjusted and PCR adjusted for reinfections by
genotyping) and compared by survival analysis using the
Kaplan-Meier product limit formula [22]. In the PCR-unadjusted
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analysis, recurrences were treated as treatment failures and all
other events (withdrawal, protocol deviations, occurrence of
P. vivax) resulted in censoring at the time of that event, or at the
time of their last follow-up visit in case of loss to follow-up. A
similar strategy was used for the PCR-adjusted analysis except
that patients with new P. falciparum infections were censored at
Figure 1. Trial proﬁle. *All 374 patients who provided informed consent and were screened for glucose-6-phosphate dehydrogenase deﬁciency were
found to have normal levels of enzyme activity. **Five subjects failed screening: 4 had mixed infections with Plasmodium vivax, and 1 was infected by
P. vivax instead of Plasmodium falciparum. ***Seven individuals allocated to the dihydroartemisinin-piperaquine (DHP)–only arm were accidently given
DHP plus primaquine (DHP + primaquine [PQ]) owing to human error. To maintain the balance within the block randomization, 7 subjects randomized to
the DHP + PQ group within the same blocks of 4 were also excluded. Abbreviation: DHP, dihydroartemisinin-piperaquine.
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the time of parasite reappearance [22]. Unadjusted Kaplan-
Meier survival analysis was also used to compare the cumula-
tive risk of gametocyte development in the gametocyte-free
population on day 3, and to measure the risk of persistence of
gametocytes or appearance of new gametocytes in those game-
tocytemic on day 3. Similar criteria for censoring were used as
for the unadjusted analysis of the asexual stages. The diffe-
rence in the area under the curve of log-transformed gameto-
cyte density starting from day 3 to day 42 was compared using
the t test. Gametocyte densities are presented as the geometric
mean (95% CI) and the difference compared by geometric
mean ratio (95% CI). Adverse events on day 7 were evaluated
among patients without the sign or symptom on day 3 and
differences between the 2 groups compared by the prevalence
ratio (95% CI). Mean hemoglobin levels on days 7 and 42
were analyzed with a generalized linear model, adjusted for
the baseline hemoglobin levels on day 0, and results expressed
as mean difference.
RESULTS
Evaluable Population
A total of 374 individuals were randomized; 186 received
DHP + PQ and 188 DHP-only. Of the 374, 25 (6.6%) were
excluded from analysis (15 and 10 subjects from the
DHP + PQ and DHP-only groups, respectively; Figure 1).
Thus, 171 subjects in the DHP + PQ arm and 178 subjects in
the DHP-only arm contributed to the modiﬁed intent-to-treat
analysis, of whom 41 and 31, respectively, had gametocytes on
day 3. Baseline characteristics on day 3 were comparable
between the groups (Table 1). During the follow-up period, 9
and 11 subjects from the DHP + PQ and DHP-only groups,
respectively, were censored (7 took prohibited drugs, 10
moved from the study area, 3 withdrew from the study).
Gametocyte Responses
The prevalence of gametocytemia was slightly but not signiﬁ-
cantly higher among the DHP + PQ group on day 3 just prior
to the administration of PQ (PR = 1.38 [95% CI, .91–2.09],
P = .13). By day 7 (4 days after PQ administration), the ratio
had changed to PR = 0.93 (95% CI, .54–1.58, P = .78), and by
day 14 the prevalence of gametocytes in the DHP + PQ group
was 16.6-fold lower than in the DHP-only arm (PR = 0.06
[95% CI, .01–.47], P < .0001; Figure 2). No one developed mi-
croscopically patent gametocytes among the patients who
were gametocyte free on day 3. Among those who were game-
tocytemic on day 3, patients in the DHP-only group remained
gametocytemic for longer (hazard ratio [HR], 2.42 [95% CI,
1.39–4.19], P = .002; Figure 3). The geometric mean gameto-
cyte densities were lower in the DHP + PQ group (157/µL Ta
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Figure 2. Gametocyte prevalence and prevalence ratio of the 2 regimens (black bar = dihydroartemisinin-piperaquine (DHP) plus primaquine; white
bar = DHP alone) during the 42-day follow-up period. Abbreviations: CI, conﬁdence interval; DHP, dihydroartemisinin-piperaquine; PQ, primaquine.
Figure 3. Kaplan-Meier survival curves of gametocyte clearance by treatment regimen. Abbreviations: CI, conﬁdence interval; DHP, dihydroartemisinin-
piperaquine; PQ, primaquine.
690 • CID 2013:56 (1 March) • Sutanto et al
 by guest on M
arch 25, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
[95% CI, 111–222] vs 330/µL [95% CI, 197–554]; geometric
mean ratio 0.47 [95% CI, .26–.88], P = .018).
Therapeutic Response on Asexual Stages by Day 42
Primaquine did not affect asexual stages of P. falciparum. The
PCR-unadjusted recurrence rates were 1.3% (2 subjects) and
0.6% (1 subject) in the DHP + PQ and DHP-only groups, re-
spectively (HR, 0.87 [95% CI, .39–1.97], P = .913). Molecular
genotyping suggested that all 3 recurrences were due to
reinfections.
Hemoglobin Measurements and Adverse Events
Hemoglobin levels were much the same between the 2 study
arms (day 0: mean difference [MD], −.09 g/dL [95% CI, −.54
to .36]; day 7: MD, −0.02 g/dL [95% CI, −0.43 to 0.39]; day
42: MD, −0.03 g/dL [95% CI, −0.39 to 0.33]). The main com-
plaints reported on day 7 were headache, fatigue and weak-
ness, nausea and vomiting, abdominal pain, diarrhea, pruritus,
and paresthesia, with similar numbers in both arms (Table 2).
DISCUSSION
Dihydroartemisinin-piperaquine effectively treated falciparum
malaria and successfully prevented the appearance of new ga-
metocytes detectable by microscopy. The addition of a single
dose of PQ reduced gametocyte densities and enhanced game-
tocyte clearance and shortened the median clearance time by
about 1 week, resulting in overall lower gametocyte carriage.
By day 14, gametocytes were undetectable in all but 1 patient
(0.6%) taking DHP + PQ compared to 9.6% (17 patients)
taking DHP alone. Primaquine had no additional effect
against asexual blood stages of P. falciparum. These results are
consisted with previous reports in symptomatic malaria pa-
tients treated with artemisinins or ACTs showing that a single
dose of PQ suppresses and quickly eliminates persistent
mature blood-stage gametocytemia that were not affected by
the artemisinins [12, 23–24].
Concerns exist about the potential for a one-off dose of PQ
to induce hemolysis, especially in G6PD-deﬁcient individuals
[25]. A recent study from Tanzania suggested that coadminis-
tration of artemisinins with PQ may be associated with mild
asymptomatic hemolysis and transient reductions in hemoglo-
bin concentrations even in individuals with the wild-type ge-
notype [26]. This study used genotyping and screened for the
most common mutation associated with G6PD deﬁciency in
Tanzania (G6PD A). As 140 mutations are known to be po-
tentially associated with G6PD deﬁciency, one possible expla-
nation suggested by the authors is that patients with less
common mutations causing G6PD deﬁciency may have been
misclassiﬁed. Functional screening tests based on enzyme ac-
tivity that measures the NADPH production capacity of
G6PD, such as used in our study, do not have this limitation.
We found that mean hemoglobin concentrations by day 7 and
42 were similar in both groups in this selected sample.
However, the sample size was too small to draw more deﬁni-
tive conclusions about the safety of a single dose of 0.75 mg/kg
PQ, as the study was not designed with safety as primary
endpoint and excluded patients with G6PD deﬁciency.
There is typically a 7- to 15-day delay after the initial acute
attack for mature P. falciparum gametocytes to become appar-
ent. The timing of the single dose of primaquine is therefore
important, especially because with a half-life of about 8 hours,
primaquine is effective only for a few days. In Thailand, game-
tocytemia peaked 3 days after start of treatment with artemisi-
nins, and gametocytes emerged in about one-quarter of
patients after treatment [27]. The median duration of the
history of fever prior to treatment was 5 days, consistent with
models by Lawpoolsri et al predicting a maximum gametocy-
temia 8 days after the onset of symptoms [19]. In Indonesia,
similar delays in seeking care are common. We therefore pro-
vided PQ the day after the last dose of DHP to maximize the
delay of PQ administration.
There are several study limitations: This was an unblinded
study, so all parties involved were potentially aware of the
treatment allocation. Second, we omitted 14 patients from the
analysis because 7 patients randomized to the DHP-only
group were accidentally provided PQ. The allocation sequence
concealment was good, and there was no indication that this
was due to preferential treatment by study staff. Third, our
study reﬂects the impact on microscopically detectable game-
tocytemia and does not exclude the persistence of subpatent
gametocytemia detectable by PCR. Our results, however, are
consistent with one previous treatment trial in Tanzania
suggesting a marked beneﬁt of primaquine in clearing sub-
microscopic gametocytes in symptomatic children receiving
Table 2. Tolerance of Dihydroartemisinin-Piperaquine (DHP)
Plus Primaquine vs DHP Alone by Day 7
Adverse
Event
DHP + PQ,
No. (%)
DHP-only
No. (%) PR (95% CI)
P
Value
Headache 13/97 (13.4) 18/96 (18.8) 0.71 (.37–1.38) .312
Fatigue 13/93 (14.0) 11/96 (11.5) 1.22 (.58–2.58) .603
Nausea 1/139 (0.7) 4/150 (2.7) 0.27 (.03–2.40) .205
Vomiting 1/163 (0.6) 1/168 (0.6) 1.03 (.07–16.34) 1.000
Abdominal pain 4/156 (2.6) 4/170 (2.4) 1.09 (.28–4.28) 1.000
Diarrhea 1/163 (0.6) 3/172 (1.7) 0.35 (.04–3.35) .623
Pruritus 0/170 (0.0) 0/177 (0.0) … …
Paresthesia 2/161 (1.2) 2/170 (1.2) 1.06 (.15–7.41) 1.000
Evaluable population includes only patients without the symptoms on day 3.
Abbreviations: CI, confidence interval; DHP, dihydroartemisinin-piperaquine;
PQ, primaquine; PR, prevalence ratio.
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sulphadoxine-pyrimethamine-artesunate [24]. By contrast,
another trial in Sudan that aimed to eliminate submicroscopic
gametocytes in asymptomatic carriers during the dry season
found no effect of PQ [28]. They hypothesized that ACT
alone is sufﬁcient to clear gametocytes in asymptomatic carri-
ers of submicroscopic infections, but that PQ is required in
patients with acute malaria with higher parasite densities.
Although haphazardly implemented, the use of single-
dose PQ to reduce malaria transmission of falciparum malaria
is widely recommended. As countries move from malaria
control to elimination, a better understanding of the risks and
beneﬁts of adding single-dose PQ to ACT has become increas-
ingly important [23]. Because a relatively high proportion of
patients had detectable gametocytes upon enrollment (21%),
sick malaria patients constitute a signiﬁcant source of trans-
missible malaria in this low-transmission areas. The addition
of PQ could thus have a major effect on malaria transmission
from treated patients by shortening the period of infectivity,
consistent with previous observations in Myanmar [23] and
other studies looking at the added value of PQ when provided
in addition to ACT or artemisinins [24]. Combined, these
ﬁndings support recommendations that in settings where
screening for G6PD deﬁciency is feasible, a single gametocidal
dose of PQ should be added to ACT in low-transmission
regions that aim to control and ultimately eliminate falciparum
malaria [1]. Further research is needed of PQ as an adjunctive
gametocidal therapy under more programmatic conditions
where routine screening for G6PD may not be feasible, includ-
ing dose-ﬁnding studies to determine the minimal safe and
effective dose [29].
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